IMR Stock Overview
Imricor Medical Systems, Inc., a medical device company, designs, manufactures, sells, and distributes magnetic resonance imaging (MRI) compatible products for cardiac catheter ablation procedures in the United States.
Imricor Medical Systems Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.16|
|52 Week High||AU$2.10|
|52 Week Low||AU$0.10|
|1 Month Change||-43.86%|
|3 Month Change||-77.14%|
|1 Year Change||-92.16%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-88.97%|
Recent News & Updates
Will Imricor Medical Systems (ASX:IMR) Spend Its Cash Wisely?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
|IMR||AU Medical Equipment||AU Market|
Return vs Industry: IMR underperformed the Australian Medical Equipment industry which returned -30.8% over the past year.
Return vs Market: IMR underperformed the Australian Market which returned -9.6% over the past year.
|IMR Average Weekly Movement||17.6%|
|Medical Equipment Industry Average Movement||9.7%|
|Market Average Movement||9.8%|
|10% most volatile stocks in AU Market||16.5%|
|10% least volatile stocks in AU Market||4.3%|
Stable Share Price: IMR is more volatile than 90% of Australian stocks over the past 3 months, typically moving +/- 18% a week.
Volatility Over Time: IMR's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
Imricor Medical Systems, Inc., a medical device company, designs, manufactures, sells, and distributes magnetic resonance imaging (MRI) compatible products for cardiac catheter ablation procedures in the United States. The company’s principal products include the Advantage-MR EP Recorder/Stimulator system, an EP recording system and integrated cardiac stimulator; Vision-MR Ablation Catheter, which is used as an indication for treating type I atrial flutter; and Vision-MR Dispersive Electrode that is used to minimize eddy currents induced on the conductive pads during MR scanning. It also performs contract research, as well as licenses its intellectual property for use in implantable devices.
Imricor Medical Systems Fundamentals Summary
|IMR fundamental statistics|
Is IMR overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|IMR income statement (TTM)|
|Cost of Revenue||US$2.59m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.14|
|Net Profit Margin||-2,834.05%|
How did IMR perform over the long term?See historical performance and comparison
Is IMR undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for IMR?
Other financial metrics that can be useful for relative valuation.
|What is IMR's n/a Ratio?|
Price to Sales Ratio vs Peers
How does IMR's PS Ratio compare to its peers?
|IMR PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
AMT Allegra Orthopaedics
RHT Resonance Health
AHC Austco Healthcare
IMR Imricor Medical Systems
Price-To-Sales vs Peers: IMR is expensive based on its Price-To-Sales Ratio (23x) compared to the peer average (3.1x).
Price to Earnings Ratio vs Industry
How does IMR's PE Ratio compare vs other companies in the AU Medical Equipment Industry?
Price-To-Sales vs Industry: IMR is expensive based on its Price-To-Sales Ratio (23x) compared to the Australian Medical Equipment industry average (5x)
Price to Sales Ratio vs Fair Ratio
What is IMR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||23x|
|Fair PS Ratio||0.01x|
Price-To-Sales vs Fair Ratio: IMR is expensive based on its Price-To-Sales Ratio (23x) compared to the estimated Fair Price-To-Sales Ratio (0x).
Share Price vs Fair Value
What is the Fair Price of IMR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate IMR's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate IMR's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IMR's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is Imricor Medical Systems forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IMR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: IMR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: IMR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: IMR's revenue (85.2% per year) is forecast to grow faster than the Australian market (5.2% per year).
High Growth Revenue: IMR's revenue (85.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if IMR's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Imricor Medical Systems performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IMR is currently unprofitable.
Growing Profit Margin: IMR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IMR is unprofitable, and losses have increased over the past 5 years at a rate of 27.9% per year.
Accelerating Growth: Unable to compare IMR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IMR is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (32.6%).
Return on Equity
High ROE: IMR has a negative Return on Equity (-88.09%), as it is currently unprofitable.
Discover strong past performing companies
How is Imricor Medical Systems's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: IMR's short term assets ($22.7M) exceed its short term liabilities ($2.7M).
Long Term Liabilities: IMR's short term assets ($22.7M) exceed its long term liabilities ($1.7M).
Debt to Equity History and Analysis
Debt Level: IMR has more cash than its total debt.
Reducing Debt: IMR had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IMR has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: IMR has less than a year of cash runway if free cash flow continues to reduce at historical rates of 34.5% each year
Discover healthy companies
What is Imricor Medical Systems's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IMR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IMR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IMR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IMR's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as IMR has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Steve Wedan (52 yo)
Mr. Steve Wedan has been the Chief Executive Officer, President and Director of Imricor Medical Systems Inc. since May 23, 2006 and serves as its Executive Chairman. Mr. Wedan has medical device experience...
CEO Compensation Analysis
Compensation vs Market: Steve's total compensation ($USD576.74K) is above average for companies of similar size in the Australian market ($USD289.00K).
Compensation vs Earnings: Steve's compensation has increased whilst the company is unprofitable.
Experienced Management: IMR's management team is seasoned and experienced (9.9 years average tenure).
Experienced Board: IMR's board of directors are considered experienced (5.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: IMR insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 14.3%.
Imricor Medical Systems, Inc.'s employee growth, exchange listings and data sources
- Name: Imricor Medical Systems, Inc.
- Ticker: IMR
- Exchange: ASX
- Founded: 2006
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: AU$21.539m
- Shares outstanding: 143.59m
- Website: https://www.imricor.com
- Imricor Medical Systems, Inc.
- 400 Gateway Boulevard
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/28 00:00|
|End of Day Share Price||2022/06/28 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.